期刊
MOLECULES
卷 26, 期 16, 页码 -出版社
MDPI
DOI: 10.3390/molecules26165091
关键词
AA amyloidosis; AL amyloidosis; Alzheimer's disease; amyotrophic lateral sclerosis; ATTR amyloidosis; dementia; Parkinson's disease; pathology; prion; transthyretin
资金
- Ministry of Health, Labor and Welfare [20FC1022]
Amyloidosis refers to a group of protein-misfolding diseases where normally soluble proteins form insoluble amyloid fibrils. The role of amyloid fibrils in tissue damage is debated, with some studies suggesting their importance in systemic amyloidosis. In neurodegenerative diseases, oligomers rather than amyloid fibrils are thought to be responsible for cell death, leading to the development of disease-modifying therapies targeting these protein aggregates.
Amyloidosis is a term referring to a group of various protein-misfolding diseases wherein normally soluble proteins form aggregates as insoluble amyloid fibrils. How, or whether, amyloid fibrils contribute to tissue damage in amyloidosis has been the topic of debate. In vitro studies have demonstrated the appearance of small globular oligomeric species during the incubation of amyloid beta peptide (A beta). Nerve biopsy specimens from patients with systemic amyloidosis have suggested that globular structures similar to A beta oligomers were generated from amorphous electron-dense materials and later developed into mature amyloid fibrils. Schwann cells adjacent to amyloid fibrils become atrophic and degenerative, suggesting that the direct tissue damage induced by amyloid fibrils plays an important role in systemic amyloidosis. In contrast, there is increasing evidence that oligomers, rather than amyloid fibrils, are responsible for cell death in neurodegenerative diseases, particularly Alzheimer's disease. Disease-modifying therapies based on the pathophysiology of amyloidosis have now become available. Aducanumab, a human monoclonal antibody against the aggregated form of A beta, was recently approved for Alzheimer's disease, and other monoclonal antibodies, including gantenerumab, solanezumab, and lecanemab, could also be up for approval. As many other agents for amyloidosis will be developed in the future, studies to develop sensitive clinical scales for identifying improvement and markers that can act as surrogates for clinical scales should be conducted.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据